Request Deal Involvement

Korro Bio completed the merger with Frequency Therapeutics in a $170m deal.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Service Providers

Latham & Watkins

legal advisors

Latham & Watkins

White & Case

legal advisors to financial advisors

White & Case

TD Cowen

financial advisors

TD Cowen

JP Morgan

financial advisors

JP Morgan

Goodwin Procter

legal advisors

Goodwin Procter

Bank of America

financial advisors

Bank of America

Piper Sandler

financial advisors

Piper Sandler

RBC Capital Markets

financial advisors

RBC Capital Markets

Davis Polk & Wardwell

legal advisors

Davis Polk & Wardwell

Finn Partners

pr advisors

Finn Partners

or

Principals

FREQUENCY THERAPEUTICS

target

FREQUENCY THERAPEUTICS

KORRO BIO

bidder

KORRO BIO

SURVEYOR CAPITAL

bidder

SURVEYOR CAPITAL

CORMORANT ASSET MANAGEMENT

bidder

CORMORANT ASSET MANAGEMENT

ATLAS VENTURE LP

bidder

ATLAS VENTURE LP

PLATANUS

bidder

PLATANUS

QIMING VENTURE PARTNERS

bidder

QIMING VENTURE PARTNERS

MP HEALTHCARE VENTURE MANAGEMENT

bidder

MP HEALTHCARE VENTURE MANAGEMENT

EVENTIDE ASSET MANAGEMENT

bidder

EVENTIDE ASSET MANAGEMENT

FIDELITY MANAGEMENT & RESEARCH COMPANY

bidder

FIDELITY MANAGEMENT & RESEARCH COMPANY

THE INVUS GROUP LLC

bidder

THE INVUS GROUP LLC

POINT72 VENTURES

bidder

POINT72 VENTURES

VERITION FUND MANAGEMENT

bidder

VERITION FUND MANAGEMENT

MONASHEE INVESTMENT MANAGEMENT

bidder

MONASHEE INVESTMENT MANAGEMENT

SIXTY DEGREE CAPITAL

bidder

SIXTY DEGREE CAPITAL

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.


To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:

All rights reserved. Copyright © 2025 Datasite

MergerLinks - Request Credit - Korro Bio completed the merger with Frequency Therapeutics in a $170m deal.